

Tachy Times: Adenosine versus Calcium Channel Blockers for Management of Supraventricular Tachycardia

Current Topics in Pharmacy Activity Announcement

According to the American College of Cardiology (ACC) and American Heart Association (AHA), the prevalence of supraventricular tachycardia (SVT) in the general population is approximately 2.29 per 1,000 persons. When adjusted for age and sex in the United States, the incidence of paroxysmal supraventricular tachycardia, a subset of SVT, is estimated to be 36 per 100,000 persons per year. Adenosine is recommended as first line for the management of SVT, but due to side effects, the utility of calcium channel blockers for management has also been explored. Pharmacists should understand the role of calcium channel blockers in the management of SVT as there has been an increase in provider curiosity surrounding the efficacy of calcium channel blockers when adenosine is not ideal or ineffective.

This activity was originally recorded on 10/14/2025.

Learning Objectives

At the conclusion of this educational activity, the participant should be able to:

- Discuss the treatment algorithm for supraventricular tachycardia
- Describe key pharmacologic differences between adenosine and calcium channel blockers

Speaker

Madison Savidge, PharmD, MBA
PGY-2 Emergency Medicine Resident
University of Maryland

Dr. Savidge, speaker for this activity, has no financial relationships to disclose. None of the planners for this activity have any financial relationships to disclose.

CE Credits: 0.5 Contact Hours

Universal Activity Number: 0025-0000-25-087-H01-P

Target Audience: Pharmacists

Activity Type: Knowledge

Activity Launch Date: 10/14/2025

Activity Expiration Date: 10/14/2026

Fee: \$15.00

Criteria for Successful Completion

Learners must complete all activity components including viewing the audiovisual presentation and completing the activity evaluation. A link to the activity evaluation will be available upon successful completion of all other course segments. Statements of CE Credit will be available electronically via CPE Monitor within sixty (60) days of completion of the activity.

Use of Trade Names: The trade names of the drugs and delivery systems in this module are for the purpose of product identification only. This activity does not imply endorsement for any commercial products discussed.

Privacy and Confidentiality: The University of Maryland School of Pharmacy is committed to protecting the privacy of our learners. All enrollees are protected under The Family Educational Rights and Privacy Act (20 U.S.C. § 1232g; 34 CFR Part 99) (FERPA). The UMB Policy on Confidentiality and Disclosure of Student Records can be found at: <https://www.umaryland.edu/policies-and-procedures/library/academic-affairs/policies/iii-630a.php>.

To submit your continuing education credit (CE) to a professional accrediting body, we must collect personal information including, but not limited to, name, NABP ID, and date of birth. When you request CE credits, certain personal information will be provided to the professional certifying entity in order to issue Statements of Credit.

Copyright: Resources are provided for the educational benefit of our learners and are not for distribution. All information and materials provided are the property of and have been prepared by the University of Maryland Baltimore or have been granted permission for use by the copyright owner. No portion of this module may be reproduced or transmitted without written permission. All rights reserved.

Technology Requirements

Supported Internet Browsers	Windows • Internet Explorer version 11 and above • Chrome 43 and above • FireFox 4.0 (or later) MacOS • Safari 13 and above • Chrome 43 and above
Minimum Memory	8 GB (or more)
Minimum Storage	6 GB (or more)
Minimum Processor	PC: 2 GHz or faster Intel processor MacOS: Multi-core Intel processor
Minimum Internet Speeds	High speed internet connection
Other	Participants must be able to play audio (either through speakers or headphones) as well as ability to open PDF files and view and edit Word, and PPT documents.



The University of Maryland School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

**Refund Policy:**

- A refund, less a \$5 administration fee, will be provided if cancellations are requested within 15 days of purchase. Other restrictions may apply. Refund requests must be submitted in writing to CEHelp@rx.umaryland.edu.
- Refunds are not available in the following circumstances: A learner has logged into a course or series; has launched course materials; course materials have been shipped; or request is made after 15 days of the ordering date.
- Course registrations are non-transferrable.

Contact Us:

Office of Continuing Education at the University of Maryland School of Pharmacy
20 N. Pine Street
Baltimore, MD 21201
410.706.3381
CEHelp@rx.umaryland.edu

To learn more or register, visit <https://ce.pharmacy.umaryland.edu>